Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method

Inclusion Criteria: * Subjects must require a routine Tev-Tropin® dose that does not exceed 2.5 mg in one injection (0.5 mL) using the dosing schedule individualized for each patient by their prescribing physician * Male, age 7-17 years, with the capability to provide assent, as determined by the investigator and/or parent or legal guardian * Clinically definite growth hormone deficiency as previously diagnosed by the investigator or other physician * Subjects must be using Tev-Tropin® prior to enrollment for 28 days * Informed consent signed by parent(s) or legal custodian of patient prior to study entry and patient assent as determined by the investigator and/or subject's parent or legal custodian Exclusion Criteria: * More than one subcutaneous injection per Tev-Tropin® dose * Female gender * Use of any other needle-free injection device at any time * Current use of another human growth hormone product other than Tev-Tropin® * Concurrent treatment with other routine injectable medications * History of benign intracranial hypertension * Significant communication difficulties, or medical or psychiatric condition, that affects the subject's and/or caregiver's ability to perform the necessary functions to complete the study, or any condition which the investigator in their medical judgment thinks may interfere with participation in the study * Use of an investigational drug within 30 days prior to randomization * Contraindications related to routine use of Tev-Tropin® as per investigators' medical judgment (e.g., subjects with closed epiphyses, active proliferative or severe non-proliferative diabetic retinopathy, active malignancy, acute critical illness, or Prader-Willi syndrome who are severely obese or have severe respiratory impairment) * Current participation in another pharmaceutical or device study * Previous participation in this study